Results 1 to 10 of about 158,239 (191)

Comparison of early versus late addition of granulocyte and monocyte adsorption for incomplete remission induction in ulcerative colitis. [PDF]

JGH Open
Background and aim Ulcerative colitis (UC) is characterized by repeated relapse and remission. Because no fundamental therapeutic strategy has been established, the treatment goal is generally to maintain the remission phase for a long period after rapid
Tominaga K, Kanazawa M, Watanabe S, Tanaka T, Kojimahara S, Masuyama S, Abe K, Kanamori A, Yamamiya A, Sugaya T, Goda K, Fujita Y, Yoshihara S, Haruyama Y, Irisawa A.   +14 more
europepmc   +2 more sources

Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy

Annals of Medicine, 2022
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare clinical syndrome with a high mortality rate. There is no biomarker to predict the early therapeutic response.
Zhengjie Hua, Lingbo He, Ruoxi Zhang, Menghan Liu, Zhao Wang, Yini Wang   +5 more
doaj   +1 more source

Remission after Six Months of Induction Immunosuppressive Treatment with Mycofenolate Mofetil and Prednisolone in Patients with Lupus Nephritis: A Descriptive Cross-sectional Study

Journal of Nepal Medical Association, 2021
Introduction: Treatment of lupus nephritis consists of six months of induction immunosuppression followed by years of maintenance immunosuppression.
Shailendra Shrestha, Rahul Yadav
doaj   +1 more source

Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials

EClinicalMedicine, 2020
Background: The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear. Methods: We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD ...
Ole Haagen Nielsen, Casper Steenholdt, Carsten Bogh Juhl, Gerhard Rogler   +3 more
doaj   +1 more source

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study [PDF]

Intestinal Research, 2021
Background/Aims The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718).
Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul   +7 more
doaj   +1 more source

A case of regression of atypical dense deposit disease without C3 deposition in a child [PDF]

Korean Journal of Pediatrics, 2010
Dense deposit disease (DDD) is a rare disorder characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidneys. The diagnosis is made in most patients between 5 and 15 years of age, and within 10
Min Sun Kim, Pyoung Han Hwang, Mung Jae Kang, Dae-Yeol Lee   +3 more
doaj   +1 more source

Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

Arthritis Research & Therapy, 2018
Background The aim of this study was to assess the outcomes of remission induction in patients with IgG4-related disease (IgG4-RD) in our cohort, and to investigate the characteristics, prognosis, and risk factors in the patients failed of remission ...
Liwen Wang, Panpan Zhang, Mu Wang, Ruie Feng, Yamin Lai, Linyi Peng, Yunyun Fei, Xuan Zhang, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wen Zhang   +11 more
doaj   +1 more source

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients

Turkish Journal of Internal Medicine, 2021
Introduction With the introduction of FLT3 inhibitors in recent years, the presence of FLT3 mutation in newly diagnosed acute myeloid leukemia (AML) patients has become more important.
Mehmet Baysal, Nihan Alkis, Serap Baysal
doaj   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? [PDF]

, 2009
5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine.
Lakatos, Péter László
core   +2 more sources